Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 4:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 661 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: nicotinic acid Clear all
Not listed Not applicable Interventional

Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors

NCT02015728
View directory record Official record
Conditions
Recurrent Childhood Brain Tumor
Interventions
Tumor biology testing, Temozolomide, Etoposide, Sorafenib, Everolimus, Erlotinib, Dasatinib
Device · Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Month to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 3, 2026, 4:13 PM EDT
Active, not recruiting Phase 1 Interventional

Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer

NCT01187199
View directory record Official record
Conditions
Advanced Cancer
Interventions
Temsirolimus, Bevacizumab, Paclitaxel, Sorafenib, Carboplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 3, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

NCT00110994
View directory record Official record
Conditions
Cancer, Melanoma
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo, Dacarbazine
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
14
States / cities
Tucson, Arizona • Aurora, Colorado • Lakeland, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 3, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma

NCT00901901
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Sorafenib (Nexavar, BAY43-9006), Erlotinib (Tarceva), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
23
States / cities
San Francisco, California • Washington D.C., District of Columbia • Gainesville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 3, 2026, 4:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma

NCT02279719
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
BBI608, BBI503, Sorafenib
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
29
States / cities
Gilbert, Arizona • Phoenix, Arizona • Coronado, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 3, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer

NCT00244972
View directory record Official record
Conditions
Advanced Malignant Neoplasm
Interventions
Laboratory Biomarker Analysis, Sorafenib Tosylate, Tipifarnib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 3, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

NCT00445588
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
erlotinib hydrochloride, sorafenib tosylate, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 3, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

Sorafenib and Bortezomib in Treating Patients With Advanced Cancer

NCT00303797
View directory record Official record
Conditions
Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Stage III Multiple Myeloma, Stage IV Chronic Lymphocytic Leukemia, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
17-N-allylamino-17-demethoxygeldanamycin/bortezomib, sorafenib tosylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Oct 3, 2026, 4:13 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis

NCT04166396
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Resveratrol, NR, Placebo
Drug · Dietary Supplement
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 3, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Study to Test GSK256073 in Patients With Dyslipidemia

NCT00903617
View directory record Official record
Conditions
Dyslipidaemias, Dyslipidemias
Interventions
GSK256073, Placebo, Niaspan
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Pembroke Pines, Florida • Indianapolis, Indiana • Louisville, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 3, 2026, 4:13 PM EDT
Recruiting Phase 2 Interventional

Nicotinamide Mononucleotide in Patients Undergoing Cardiac Surgery

NCT07013591
View directory record Official record
Conditions
Cardiac Surgery
Interventions
MIB-626, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 3, 2026, 4:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer

NCT01658878
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Nivolumab, Sorafenib, Ipilimumab, Cabozantinib
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Pensacola, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 3, 2026, 4:13 PM EDT
Completed Not applicable Interventional Results available

Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment

NCT04078178
View directory record Official record
Conditions
Cognition Disorders in Old Age, Mild Cognitive Impairment, Cognitive Decline
Interventions
Niagen, Placebo Comparator
Dietary Supplement
Lead sponsor
Steven E Arnold, MD
Other
Eligibility
60 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 3, 2026, 4:13 PM EDT
Completed Early Phase 1 Interventional

Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer

NCT00405366
View directory record Official record
Conditions
Kidney Cancer
Interventions
sorafenib tosylate
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 3, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma

NCT00461851
View directory record Official record
Conditions
Bladder Cancer
Interventions
Gemcitabine, Carboplatin, Sorafenib
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Oct 3, 2026, 4:13 PM EDT
Terminated Phase 2 Interventional Results available

Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas

NCT01338857
View directory record Official record
Conditions
neurofibromatosis1 (NF1), Recurrent or Progressive Optic Pathway Gliomas (OPG), Recurrent or Progressive Low-grade Glioma
Interventions
Sorafenib (Nexavar)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
2 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 3, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program

NCT05878119
View directory record Official record
Conditions
Healthy
Interventions
Investigational Product - MIB 626, Placebo, Standardized, progressive, high intensity, multidimensional exercise, Usual Physical Activity
Drug · Other
Lead sponsor
Metro International Biotech, LLC
Industry
Eligibility
19 Years to 40 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 3, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer

NCT02349867
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Recurrent Pancreatic Carcinoma
Interventions
Gemcitabine, Sorafenib, Vorinostat, 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, RosetteSep, DEPfff
Drug · Radiation · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 19, 2022 · Synced Oct 3, 2026, 4:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective

NCT01754987
View directory record Official record
Conditions
Metastatic Hepatocellular Carcinoma, Advanced Liver Cancer
Interventions
Ascorbic Acid + Sorafenib, Sorafenib
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 3, 2026, 4:13 PM EDT
Completed Phase 1Phase 2 Interventional

RDEA119 and Sorafenib Combination Dose Escalation Study

NCT00785226
View directory record Official record
Conditions
Advanced Cancer
Interventions
RDEA119, Sorafenib
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Los Angeles, California • Las Vegas, Nevada • Albany, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 3, 2026, 4:13 PM EDT
Completed Phase 2 Interventional

Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease

NCT02140814
View directory record Official record
Conditions
Polycystic Kidney Disease
Interventions
Niacinamide
Dietary Supplement
Lead sponsor
Alan Yu, MB, BChir
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 3, 2026, 4:13 PM EDT
Completed No phase listed Observational

Plaque Inflammation and Dysfunctional HDL in AIM-HIGH

NCT00880178
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Coronary Disease, Atherosclerosis, Myocardial Infarction
Interventions
Simvastatin and Extended-Release niacin, Simvastatin
Drug
Lead sponsor
University of Washington
Other
Eligibility
45 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 3, 2026, 4:13 PM EDT
Terminated Phase 1 Interventional

Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis

NCT00767468
View directory record Official record
Conditions
Liver Cancer
Interventions
sorafenib tosylate
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Oct 3, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors

NCT01518413
View directory record Official record
Conditions
Rhabdomyosarcoma and Other Soft Tissue Sarcomas, Ewing's Sarcoma Family of Tumors, Osteosarcoma, Neuroblastoma, Brain Tumors
Interventions
sorafenib, irinotecan
Drug
Lead sponsor
HMeany
Other
Eligibility
2 Years to 22 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2015 · Synced Oct 3, 2026, 4:13 PM EDT